Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AARON S FARBERG

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1134480239
CMS profile
1392313
Location
ROCKWALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$395,777.54

486 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 10; records 151–200 of 486 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AARON S FARBERG

NPI 1134480239 · CMS profile ID 1392313

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

ROCKWALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 10; records 151–200 of 486 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134480239?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AARON S FARBERG, NPI 1134480239, CMS profile ID 1392313. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 10; records 151–200 of 486 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134480239?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AARON S FARBERG, NPI 1134480239, CMS profile ID 1392313. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 10; records 151–200 of 486 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134480239?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AARON S FARBERG, NPI 1134480239, CMS profile ID 1392313, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 10; records 151–200 of 486 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1134480239?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

486 matching records · $395,777.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 486 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 486.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ortho Dermatologics, a division of Bausch Health US, LLC $8.2309/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051596573 CMS
PFIZER INC. $16.2709/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050425873 CMS
Galderma Laboratories, L.P. $24.8608/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694109 CMS
Galderma Laboratories, L.P. $29.2508/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694113 CMS
Galderma Laboratories, L.P. $10.0008/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694115 CMS
Arcutis Biotherapeutics, Inc. $8.6508/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044633675 CMS
Dermavant Sciences, Inc. $102.4008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991183293 CMS
Janssen Biotech, Inc. $19.1808/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988421293 CMS
MAYNE PHARMA COMMERCIAL LLC $4.8408/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060851857 CMS
Lilly USA, LLC $21.9108/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031232125 CMS
UCB, Inc. $16.3208/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021913073 CMS
Galderma Laboratories, L.P. $17.1508/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694101 CMS
Galderma Laboratories, L.P. $4.1008/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694103 CMS
Galderma Laboratories, L.P. $20.0008/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694107 CMS
PFIZER INC. $1.7608/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050599031 CMS
Janssen Biotech, Inc. $5,775.0008/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988420887 CMS
E.R. Squibb & Sons, L.L.C. $27.2608/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016181203 CMS
Galderma Laboratories, L.P. $18.3808/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694097 CMS
Incyte Corporation $5.9508/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044677532 CMS
Regeneron Healthcare Solutions, Inc. $20.6308/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999167795 CMS
Janssen Biotech, Inc. $21.4408/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988421253 CMS
Dermavant Sciences, Inc. $12.9308/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991183289 CMS
Janssen Biotech, Inc. $121.8608/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988420897 CMS
Janssen Biotech, Inc. $1,503.9608/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988420909 CMS
Janssen Biotech, Inc. $4.7608/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988421263 CMS
Janssen Biotech, Inc. $8.0908/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988421273 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.3308/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051596567 CMS
Sun Pharmaceutical Industries Inc. $281.3708/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816789 CMS
Sun Pharmaceutical Industries Inc. $6,400.0008/19/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816793 CMS
Sun Pharmaceutical Industries Inc. $40.4608/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816795 CMS
Sun Pharmaceutical Industries Inc. $19.8708/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816797 CMS
Sun Pharmaceutical Industries Inc. $40.6808/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816799 CMS
Sun Pharmaceutical Industries Inc. $64.0308/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816801 CMS
Sun Pharmaceutical Industries Inc. $12.1308/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816803 CMS
Sun Pharmaceutical Industries Inc. $48.0008/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816805 CMS
Sun Pharmaceutical Industries Inc. $88.1208/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816807 CMS
E.R. Squibb & Sons, L.L.C. $4,557.0008/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016181079 CMS
Sun Pharmaceutical Industries Inc. $26.5808/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053774881 CMS
Sun Pharmaceutical Industries Inc. $123.2008/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059816791 CMS
Dermavant Sciences, Inc. $19.9008/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991183285 CMS
Galderma Laboratories, L.P. $15.0808/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694083 CMS
Galderma Laboratories, L.P. $25.0008/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694085 CMS
Galderma Laboratories, L.P. $25.0008/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694089 CMS
Galderma Laboratories, L.P. $14.0008/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694091 CMS
Galderma Laboratories, L.P. $52.6508/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694095 CMS
Janssen Biotech, Inc. $4.0508/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988421283 CMS
MAYNE PHARMA COMMERCIAL LLC $15.8808/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060851853 CMS
Galderma Laboratories, L.P. $1,875.0008/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694077 CMS
Galderma Laboratories, L.P. $1,875.0008/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059694081 CMS
Arcutis Biotherapeutics, Inc. $7.6708/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044633689 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $22,972.80 98
PY2020 $18,486.98 48
PY2021 $53,841.72 139
PY2022 $131,622.77 154
PY2023 $395,777.54 486
PY2024 $504,408.50 449
PY2025 $419,066.13 406

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,260.80 2
PY2025 Principal investigator $257,245.52 53
PY2024 Principal investigator $63,004.00 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,777.50 12/22/2025 Non-covered Recipient Entity
Reveal Research Institute Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226082858
Principal investigator 1 Incyte Corporation $3,038.90 12/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,278.32 12/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184279324
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $51,063.75 12/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223290008
Principal investigator 1 Incyte Corporation $1,968.30 12/04/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,559.45 12/04/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184269511
Principal investigator 1 Incyte Corporation $1,732.40 11/26/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582265
Principal investigator 1 SANOFI US SERVICES INC. $3,386.70 11/24/2025 Non-covered Recipient Entity
Reveal Research Institute Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226082827
Principal investigator 1 Incyte Corporation $3,915.90 11/20/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582261
Principal investigator 1 Incyte Corporation $1,533.10 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582167
Principal investigator 1 Incyte Corporation $1,824.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582171
Principal investigator 1 Incyte Corporation $1,824.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582175
Principal investigator 1 Incyte Corporation $2,748.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582180
Principal investigator 1 Incyte Corporation $2,748.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582184
Principal investigator 1 Incyte Corporation $2,748.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582188
Principal investigator 1 Incyte Corporation $2,748.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582191
Principal investigator 1 Incyte Corporation $2,748.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582194
Principal investigator 1 Incyte Corporation $62.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582198
Principal investigator 1 Incyte Corporation $62.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582203
Principal investigator 1 Incyte Corporation $62.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582207
Principal investigator 1 Incyte Corporation $62.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582211
Principal investigator 1 Incyte Corporation $1,917.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582215
Principal investigator 1 Incyte Corporation $1,987.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582220
Principal investigator 1 Incyte Corporation $1,987.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582223
Principal investigator 1 Incyte Corporation $1,987.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582227
Principal investigator 1 Incyte Corporation $101.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582234
Principal investigator 1 Incyte Corporation $101.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582238
Principal investigator 1 Incyte Corporation $101.00 11/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240582242
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,580.98 11/10/2025 Non-covered Recipient Entity
DERMATOLOGY TREATMENT AND RESEARCH CENTER
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190304877
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,755.75 11/03/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,722.91 10/29/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184253801
Principal investigator 1 Incyte Corporation $1,968.30 10/28/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582253
Principal investigator 1 Incyte Corporation $1,854.90 10/23/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582249
Principal investigator 1 Incyte Corporation $4,506.00 10/16/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582258
Principal investigator 1 SANOFI US SERVICES INC. $3,741.30 09/15/2025 Non-covered Recipient Entity
Reveal Research Institute Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226082781
Principal investigator 1 Incyte Corporation $5,884.20 09/04/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $886.38 09/04/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184235331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,550.57 08/14/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184228631
Recipient Eli Lilly and Company $1,230.00 08/08/2025 Covered Recipient Physician A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187873293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,265.31 07/31/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184223002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,027.10 07/22/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184217963
Principal investigator 1 SANOFI US SERVICES INC. $6,342.30 07/14/2025 Non-covered Recipient Entity
Reveal Research Institute Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226082726
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,500.00 07/11/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223282592
Principal investigator 1 SANOFI US SERVICES INC. $4,815.00 06/09/2025 Non-covered Recipient Entity
Reveal Research Institute Pllc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226082679
Principal investigator 1 SANOFI US SERVICES INC. $10,917.90 05/27/2025 Non-covered Recipient Entity
Reveal Research Institute Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226082673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,576.00 03/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184174360
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,500.00 03/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184174362
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,118.00 03/19/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184174364
Recipient Regeneron Pharmaceuticals, Inc. $30.80 03/14/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117435
Principal investigator 1 SANOFI US SERVICES INC. $5,328.00 03/10/2025 Non-covered Recipient Entity
Reveal Research Institute Pllc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226082613
Principal investigator 1 SANOFI US SERVICES INC. $3,800.00 02/24/2025 Non-covered Recipient Entity
Reveal Research Institute Pllc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226082621
Principal investigator 1 Incyte Corporation $1,500.00 01/29/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582269
Principal investigator 1 Incyte Corporation $1,500.00 01/29/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582274
Principal investigator 1 Incyte Corporation $7,500.00 01/29/2025 Non-covered Recipient Entity
REVEAL RESEARCH INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240582278
Principal investigator 1 SANOFI US SERVICES INC. $27,033.30 01/21/2025 Non-covered Recipient Entity
Reveal Research Institute Pllc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226082593